{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:36:51Z","timestamp":1776695811520,"version":"3.51.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,11]]},"DOI":"10.7759\/cureus.22115","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T11:38:33Z","timestamp":1644579513000},"source":"Crossref","is-referenced-by-count":1,"title":["Extra-Axial Skeletal Metastasis of Malignant Melanoma: Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Keerthi","family":"Gullapalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyal","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Mosalem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venumadhavi","family":"Gogineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Tikaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch1","article-title":"Epidemiology of melanoma","author":"Matthews NH","year":"2017","unstructured":"Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho E. Epidemiology of melanoma. Cutaneous Melanoma: Etiology and Therapy. Ward WH, Farma JM (ed): Codon Publications, Brisbane, Australia; 2017. 3-22. 10.15586\/codon.cutaneousmelanoma.2017.ch1"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcsup.2013.07.012","article-title":"Melanoma epidemiology, biology and prognosis","volume":"11","author":"Ali Z","year":"2013","unstructured":"Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl. 2013, 11:81-91. 10.1016\/j.ejcsup.2013.07.012","journal-title":"EJC Suppl"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01652","article-title":"An Italian retrospective survey on bone metastasis in melanoma: impact of immunotherapy and radiotherapy on survival","volume":"10","author":"Mannavola F","year":"2020","unstructured":"Mannavola F, Mandala M, Todisco A, et al.. An Italian retrospective survey on bone metastasis in melanoma: impact of immunotherapy and radiotherapy on survival. Front Oncol. 2020, 10:1652. 10.3389\/fonc.2020.01652","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch6","article-title":"Clinical presentation and staging of melanoma","author":"Ward WH","year":"2017","unstructured":"Ward WH, Lambreton F, Goel N, Yu JQ, Farma JM. Clinical presentation and staging of melanoma. Cutaneous Melanoma: Etiology and Therapy. Ward WH, Farma JM (ed): Codon Publications, Brisbane, Australia; 2017. 79-89. 10.15586\/codon.cutaneousmelanoma.2017.ch6"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/647684","article-title":"Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors","volume":"2012","author":"Tas F","year":"2012","unstructured":"Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012, 2012:647684. 10.1155\/2012\/647684","journal-title":"J Oncol"},{"key":"ref6","article-title":"Survival rates of patients with metastatic malignant melanoma","volume":"7","author":"Sandru A","year":"2014","unstructured":"Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014, 7:572-576.","journal-title":"J Med Life"},{"key":"ref7","article-title":"Metastatic melanoma in the femur - case report with review of literature: a pathologist's point of view","volume":"9","author":"Costache M","year":"2014","unstructured":"Costache M, Stoica A, Contolenco A, Costache D, Cirstoiu C, Simionescu O, George S. Metastatic melanoma in the femur - case report with review of literature: a pathologist's point of view. Maedica (Bucur). 2014, 9:62-67.","journal-title":"Maedica (Bucur)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000466","article-title":"Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome","volume":"28","author":"G\u00f3mez-Le\u00f3n N","year":"2018","unstructured":"G\u00f3mez-Le\u00f3n N, Pacheco-Barcia V, Ballesteros AI, Fraga J, Colomer R, Friera A. Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome. Melanoma Res. 2018, 28:562-570. 10.1097\/CMR.0000000000000466","journal-title":"Melanoma Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2017.321","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo F","year":"2017","unstructured":"Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F. Bone metastases: an overview. Oncol Rev. 2017, 11:321. 10.4081\/oncol.2017.321","journal-title":"Oncol Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.5.9.3306","article-title":"Pathophysiology of bone metastases","volume":"5","author":"Berenson J","year":"2006","unstructured":"Berenson J, Rajdev L, Broder M. Pathophysiology of bone metastases. Cancer Biol Ther. 2006, 5:1078-1081. 10.4161\/cbt.5.9.3306","journal-title":"Cancer Biol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.fas.2011.10.008","article-title":"Pathologic fracture of the distal tibia secondary to melanoma: a case report of a very rare entity","volume":"18","author":"Herrera-Perez M","year":"2012","unstructured":"Herrera-Perez M, Ayala-Rodrigo A, Sanchez-Hernandez P, Rodriguez-Rodriguez LM. Pathologic fracture of the distal tibia secondary to melanoma: a case report of a very rare entity. Foot Ankle Surg. 2012, 18:e18-e20. 10.1016\/j.fas.2011.10.008","journal-title":"Foot Ankle Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-8-70","article-title":"Rare clinical experiences for surgical treatment of melanoma with osseous metastases in Taiwan","volume":"8","author":"Huang KY","year":"2007","unstructured":"Huang KY, Wang CR, Yang RS. Rare clinical experiences for surgical treatment of melanoma with osseous metastases in Taiwan. BMC Musculoskelet Disord. 2007, 8:70. 10.1186\/1471-2474-8-70","journal-title":"BMC Musculoskelet Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch CM","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, et al.. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009, 27:6199-6206. 10.1200\/JCO.2009.23.4799","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald JE","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al.. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017, 67:472-492. 10.3322\/caac.21409","journal-title":"CA Cancer J Clin"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert C","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al.. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019, 381:626-636. 10.1056\/NEJMoa1904059","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.09.003","article-title":"State of melanoma: an historic overview of a field in transition","volume":"35","author":"Karapetyan L","year":"2021","unstructured":"Karapetyan L, Kirkwood JM. State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am. 2021, 35:1-27. 10.1016\/j.hoc.2020.09.003","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer R","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H et. al.. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020, 395:1835-1844. 10.1016\/S0140-6736(20)30934-X","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.01.008","article-title":"Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy","volume":"131","author":"Laggner U","year":"2009","unstructured":"Laggner U, Lopez JS, Perera G, et al.. Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy. Clin Immunol. 2009, 131:367-373. 10.1016\/j.clim.2009.01.008","journal-title":"Clin Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5269062","article-title":"Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors","volume":"2019","author":"Rogiers A","year":"2019","unstructured":"Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B. Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. J Oncol. 2019, 2019:5269062. 10.1155\/2019\/5269062","journal-title":"J Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik AA","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, et al.. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021, 39:2656-2666. 10.1200\/JCO.21.00612","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/62328-extra-axial-skeletal-metastasis-of-malignant-melanoma-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:36Z","timestamp":1707507516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/62328-extra-axial-skeletal-metastasis-of-malignant-melanoma-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.22115","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,11]]}}}